Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Magbanua MJM, Ahmed Z, Sayaman RW, Brown Swigart L, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Perlmutter J, Pohlmann P, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Magbanua MJM, et al. Clin Cancer Res. 2024 Jun 3;30(11):2444-2451. doi: 10.1158/1078-0432.CCR-23-2928. Clin Cancer Res. 2024. PMID: 38470545 Free PMC article.
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. DiPeri TP, et al. Among authors: pohlmann pr. Cancer Discov. 2024 May 1;14(5):828-845. doi: 10.1158/2159-8290.CD-23-0838. Cancer Discov. 2024. PMID: 38358339 Free PMC article. Clinical Trial.
Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial.
Wang H, Yee D, Potter D, Jewett P, Yau C, Beckwith H, Watson A, O'Grady N, Wilson A, Brain S, Pohlmann P, Blaes A. Wang H, et al. Res Sq [Preprint]. 2023 May 31:rs.3.rs-2588168. doi: 10.21203/rs.3.rs-2588168/v1. Res Sq. 2023. Update in: Breast Cancer Res Treat. 2024 Apr;204(3):589-597. doi: 10.1007/s10549-023-07214-5 PMID: 37397981 Free PMC article. Updated. Preprint.
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Lynce F, Mainor C, Donahue RN, Geng X, Jones G, Schlam I, Wang H, Toney NJ, Jochems C, Schlom J, Zeck J, Gallagher C, Nanda R, Graham D, Stringer-Reasor EM, Denduluri N, Collins J, Chitalia A, Tiwari S, Nunes R, Kaltman R, Khoury K, Gatti-Mays M, Tarantino P, Tolaney SM, Swain SM, Pohlmann P, Parsons HA, Isaacs C. Lynce F, et al. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23297559. doi: 10.1101/2023.12.04.23297559. medRxiv. 2023. Update in: Nat Commun. 2024 Mar 27;15(1):2691. doi: 10.1038/s41467-024-46961-x PMID: 38105958 Free PMC article. Updated. Preprint.
HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Pohlmann PR, Graham D, Wu T, Ottaviano Y, Mohebtash M, Kurian S, McNamara D, Lynce F, Warren R, Dilawari A, Rao S, Mainor C, Swanson N, Tan M, Isaacs C, Swain SM. Pohlmann PR, et al. Breast Cancer Res Treat. 2022 Dec;196(3):571-581. doi: 10.1007/s10549-022-06743-9. Epub 2022 Oct 25. Breast Cancer Res Treat. 2022. PMID: 36280642 Free PMC article. Clinical Trial.
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma.
Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH. Hatakeyama H, et al. Among authors: pohlmann pr. PLoS One. 2010 Sep 13;5(9):e12702. doi: 10.1371/journal.pone.0012702. PLoS One. 2010. PMID: 20856931 Free PMC article.
Isolevuglandins as a gauge of lipid peroxidation in human tumors.
Yan HP, Roberts LJ, Davies SS, Pohlmann P, Parl FF, Estes S, Maeng J, Parker B, Mernaugh R. Yan HP, et al. Free Radic Biol Med. 2017 May;106:62-68. doi: 10.1016/j.freeradbiomed.2017.02.020. Epub 2017 Feb 9. Free Radic Biol Med. 2017. PMID: 28189846 Free PMC article.
67 results